标题
Immunotherapy Advances for Epithelial Ovarian Cancer
作者
关键词
-
出版物
Cancers
Volume 12, Issue 12, Pages 3733
出版商
MDPI AG
发表日期
2020-12-14
DOI
10.3390/cancers12123733
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prognostic gene expression signature for high-grade serous ovarian cancer
- (2020) J. Millstein et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting the folate receptor α in oncology
- (2020) Mariana Scaranti et al. Nature Reviews Clinical Oncology
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity
- (2020) Eleni Gavriilaki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
- (2020) Anders Handrup Kverneland et al. Oncotarget
- Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
- (2020) Matthew S. Block et al. Nature Communications
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Synthetic lethality guiding selection of drug combinations in ovarian cancer
- (2019) Andreas Heinzel et al. PLoS One
- Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
- (2019) Jiang Lv et al. Journal of Hematology & Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in Ovarian Cancer
- (2019) Weimin Wang et al. Surgical Oncology Clinics of North America
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum Derivatives Effects on Anticancer Immune Response
- (2019) Cédric Rébé et al. Biomolecules
- Latest developments in MUC1 immunotherapy
- (2018) Joyce Taylor-Papadimitriou et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
- (2018) Maren Knödler et al. BRITISH JOURNAL OF CANCER
- Helicase-driven activation of NFκB-COX2 mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment
- (2018) Marie-Nicole Theodoraki et al. CANCER RESEARCH
- T-cell responses toTP53"hotspot" mutations and unique neoantigens expressed by human ovarian cancers
- (2018) Drew C Deniger et al. CLINICAL CANCER RESEARCH
- Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
- (2018) Eric Pujade-Lauraine et al. Future Oncology
- Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy
- (2018) Chien-Fu Hung et al. HUMAN GENE THERAPY
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
- (2018) Janos L. Tanyi et al. Science Translational Medicine
- Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer
- (2018) Sara Bobisse et al. Nature Communications
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
- (2018) Abdi Ghaffari et al. BRITISH JOURNAL OF CANCER
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- In vivo cancer vaccination: Which dendritic cells to target and how?
- (2018) Cheryl Lai-Lai Chiang et al. CANCER TREATMENT REVIEWS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
- (2018) Shannon Grabosch et al. ONCOGENE
- Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
- (2018) Ying L. Liu et al. Current Oncology Reports
- Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
- (2018) Diana Cholakian Pearre et al. Therapeutics and Clinical Risk Management
- Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells
- (2018) John P. Murad et al. Frontiers in Immunology
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- High grade serous ovarian carcinomas originate in the fallopian tube
- (2017) S. Intidhar Labidi-Galy et al. Nature Communications
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer
- (2016) J. Krzystyniak et al. ANNALS OF ONCOLOGY
- Opportunities in immunotherapy of ovarian cancer
- (2016) G. Coukos et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
- (2016) Kari L. Ring et al. CANCER JOURNAL
- Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
- (2016) Kenneth H. Kim et al. GYNECOLOGIC ONCOLOGY
- Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
- (2016) Dmitriy Zamarin et al. GYNECOLOGIC ONCOLOGY
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
- (2016) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
- (2016) Wei Xue et al. OncoImmunology
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells
- (2015) B L Levine CANCER GENE THERAPY
- Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model
- (2015) Jyothi Thyagabhavan Mony et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
- (2015) X. Liu et al. CANCER RESEARCH
- Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity
- (2015) Tsukasa Seya et al. CANCER SCIENCE
- The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy
- (2015) E. Zsiros et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- (2015) L. Corrales et al. CLINICAL CANCER RESEARCH
- Cancer gene therapy with T cell receptors and chimeric antigen receptors
- (2015) Hans J Stauss et al. CURRENT OPINION IN PHARMACOLOGY
- Advances and prospects in adoptive cell transfer therapy for ovarian cancer
- (2015) Katarzyna Urbanska et al. Immunotherapy
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- Checkpoint blockade in combination with cancer vaccines
- (2015) Michael A. Morse et al. VACCINE
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy
- (2015) Emese Zsiros et al. OncoImmunology
- Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge
- (2015) Stefan Symeonides et al. Frontiers in Oncology
- NKG2D CARs as Cell Therapy for Cancer
- (2014) Charles L. Sentman et al. CANCER JOURNAL
- Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
- (2014) E. Galanis et al. CANCER RESEARCH
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- MUC16: molecular analysis and its functional implications in benign and malignant conditions
- (2014) Dhanya Haridas et al. FASEB JOURNAL
- A Human ErbB2-Specific T-Cell Receptor Confers Potent Antitumor Effector Functions in Genetically Engineered Primary Cytotoxic Lymphocytes
- (2014) Evripidis Lanitis et al. HUMAN GENE THERAPY
- Mechanism of Action of Immunotherapy
- (2014) Mary L. Disis SEMINARS IN ONCOLOGY
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
- (2013) C. J. Nirschl et al. CLINICAL CANCER RESEARCH
- A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
- (2013) C. L.-L. Chiang et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies therapies for ovarian cancer
- (2013) Umberto Leone Roberti Maggiore et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Major clinical research advances in gynecologic cancer in 2011
- (2012) Dong Hoon Suh et al. Journal of Gynecologic Oncology
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
- (2012) Jessica N McAlpine et al. MODERN PATHOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunobiology of human mucin 1 in a preclinical ovarian tumor model
- (2012) R A Budiu et al. ONCOGENE
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- (2012) K. Odunsi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer
- (2011) Raluca A. Budiu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
- (2011) Yu-Li Chen et al. Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
- (2011) Gina Mantia-Smaldone et al. Cancer Management and Research
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Oncolytic virotherapy of gynecologic malignancies
- (2010) Andreas D. Hartkopf et al. GYNECOLOGIC ONCOLOGY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Whole tumor antigen vaccines
- (2010) Cheryl Lai-Lai Chiang et al. SEMINARS IN IMMUNOLOGY
- The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
- (2009) Xia Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
- (2009) Peter J. Frederick et al. GYNECOLOGIC ONCOLOGY
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations
- (2008) Ann K. Folkins et al. GYNECOLOGIC ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss
- (2008) Blaise Clarke et al. MODERN PATHOLOGY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells
- (2007) Hans J. Stauss et al. BLOOD CELLS MOLECULES AND DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now